We would like to share some important news with you. After years of bringing you the latest insights, analysis and innovation news from the pharma industries, we have made the difficult decision to ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of its lead therapeutic candidate efruxifermin (EFX) this week, a fibroblast growth factor 21 analog, designed to ...